Description: Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
Home Page: www.pharnext.com
Immeuble Vivaldi
Issy-les-Moulineaux,
92130
France
Phone:
33 1 41 09 22 30
Officers
| Name | Title |
|---|---|
| Mr. Daniel E. Cohen | Director |
| Mr. Joshua Schafer | Interim CEO & Chairman |
| Mr. Ilya Chumakov Ph.D., D-Sc | Co-Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Rob Quinn Ph.D. | Chief Financial Officer |
| Mr. Xavier Paoli M.Sc. | Chief Operating Officer |
| Mr. Antoine Gravelle | Gen. Counsel |
| Ms. Susanne Dorn | Chief Regulatory Officer |
| Mr. Rodolphe Hajj | Chief Pharmacology Officer |
| Ms. Viviane Bertrand | Chief Preclinical Drug Devel. Officer |
| Mr. Philippe Rinaudo | Chief Data Science Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 24.5429 |
| Price-to-Sales TTM: | 0.0972 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 28 |